Anti -psychiatric drugs cause metabolic syndrome related molecular mechanisms and their new targets

近日，上海交通大学Bio-X研究院秦胜营团队在Molecular Psychiatry在线发表了研究论文Multi-omics analysis identifies rare variation in leptin/PPAR gene sets and hypermethylation of ABCG1 contribute to antipsychotics-induced metabolic syndromes。 The research method of comprehensive application of multiple groups of studies has deeply tapped multiple molecular marks related to metabolic syndrome (medicinal metabolic syndrome) related to anti -psychiatric drugs. It further revealed its pathogenesis, and then carried out the feasibility verification of relevant therapeutic targets, and provided new strategies for the prevention and treatment of such adverse reactions in the future.

Anti -psychiatric drug treatment is the main clinical treatment of schizophrenia and other mental diseases. However, about 40%of patients will have the adverse reaction of drug -derived metabolic syndrome after receiving the treatment of anti -psychiatric drugs, which seriously affects The quality of life of patients with schizophrenia has led to a decrease in the compliance of their medication, which brings a huge medical burden on the family and society. This paper uses multiple groups of research systems to analyze the drug -based metabolic syndrome related molecular markers and its mechanisms adopted by multiple groups of research systems.

This thesis focuses on the sub -group of patients who have metabolic syndrome after the treatment of schizophrenia and anti -psychiatric drugs. Learning and technical means, it is found that many common and rare genetic variation -related genes and pathways, as well as the occurrence of methylation areas, are related to the occurrence of pharmaceutical metabolic syndrome. Subsequently, the thorming fat metabolic disorders induced by psychiatric drugs were innovatively used to conduct large -scale RNAI screening verification on the candidate gene discovered by the group. And further verification of molecular function and target therapy in the cell and mouse model induced by psychiatric drugs, clarified the expression of the PTPN11 gene, which is related to the occurrence of medicinal metabolic syndrome, and demonstrated the targeting molecular molecular The feasibility of precision intervention of medicinal metabolic syndrome.

Dr. Zhou Wei, the BIO-X Research Institute of Shanghai Jiaotong University, Dr. Sun Jing of Jiangsu University School of Pharmacy, and Dr. Huai Cong of the BIO-X Research Institute of Shanghai Jiaotong University as the first author of this paper. Professor Qin Shengying. The Qinshengying team has long been engaged in the study of pharmaceutical genomics and individualized medicine, birth defects and disease genomics. I sincerely invite youth talents to join the research team to engage in postdoctoral research. Contact number: Teacher Zhang, 021-62932779-8202.

Resume delivery (interested, please send personal resumes and other materials to):

https://jinshuju.net/f/zqxwzt

Original link:

https://www.nature.com/articleS/S41380-022-01759-5

Want to know more exciting content, come and pay attention to BIOART biological art

- END -